Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza

Lancet

Volumn 357, Issue 9272, 2001, Pages 1937-1943

  Nicholson, Karl G ^a   Colegate, Anthony E ^b,c   Podda, Audino ^b,c   Stephenson, Iain ^a   Wood, John ^d   Ypma, Ellen ^b,c   Zambon, Maria C ^e  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b CHIRON VACCINES   (Italy)

^c Chiron Vaccines   (Netherlands)

^d NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^e PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NEUTRALIZING ANTIBODY;

ADJUVANT THERAPY; ADULT; ANTIBODY TITER; ANTIGENICITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; INFLUENZA VACCINATION; INFLUENZA VIRUS A; MALE; NORMAL HUMAN; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0035897889     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)05066-2     Document Type: Article

References (29)

1. Evolution and ecology of influenza viruses: Interspecies transmission
2. Characterization of virulent and avirulent A/chicken/Pennsylvania/83 influenza A viruses: Potential role of defective interfering RNAs in nature
3. Replication of avian influenza viruses in humans
4. Conjunctivitis in human beings caused by influenza A virus of seals
5. Avian influenza virus isolated from a woman with conjunctivitis
6. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus
7. Characterization of avian H5N1 influenza viruses from poultry in Hong Kong
8. Amouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans
9. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus
10. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts
11. Vaccines against H5N1 influenza
12. Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly
13. Molecular investigation of an outbreak of influenza
14. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serological assays
15. Quantitation and analysis of the specificity of post-immunization antibodies to influenza B viruses using single radial haemolysis
16. Standardization of inactivated influenza vaccines
17. Determinants of immunity to influenza infection in man
18. Replication of avian influenza A viruses in mammals
19. Serologic evidence of infections with avian influenza viruses
20. Pandemic influenza: A zoonosis?
21. Serum SRH antibody level as a measure of the immunity against natural and artificial A/Victoria/3/75 infections
22. Interpretation of responses and protective levels of antibody against attenuated influenza A viruses using single radial haemolysis
23. ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus
24. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans
25. DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice
26. Summary of clinical trials of influenza virus vaccines in adults
27. Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: Serological responses and clinical reactions
28. Risk of influenza A (H5N1) infection among healthcare workers exposed to patients with influenza A(H5N1), Hong Kong